Nuclear Localization of TET2 Requires Β-Catenin Activation and Correlates with Favourable Prognosis in Colorectal Cancer

Changpeng Li,Jingcai He,Fei Meng,Fuhui Wang,Hao Sun,Huizhong Zhang,Linna Dong,Mengdan Zhang,Qiaoran Xu,Lining Liang,Yuan Li,Tingting Yang,Meiai He,Tao Wang,Jiechun Lin,Jiaqi Sun,Qiuling Huang,Lin Guo,Xiaofei Zhang,Shijuan Mai,Hui Zheng

DOI: https://doi.org/10.1038/s41419-023-06038-x

2023-01-01

Cell Death and Disease

Abstract:Mutation-induced malfunction of ten-eleven translocation methylcytosine dioxygenase 2 (TET2) is widely reported in haematological malignancies. However, the role of TET2 in solid cancers, including colorectal cancer (CRC), is unclear. Here, we found that TET2 malfunction in CRC is mostly due to decreased nuclear localization and that nuclear localization of TET2 is correlated with better survival of patients. To explore the underlying mechanisms, 14 immortalized solid tumour cell lines and 12 primary CRC cell lines were used. TET2 was mostly detected in the nucleus, and it induced significant DNA demethylation and suppressed cell growth by demethylating RORA and SPARC in cell lines like SW480. While in cell lines like SW620, TET2 was observed in the cytosol and did not affect DNA methylation or cell growth. Further examination with immunoprecipitation-mass spectrometry illustrated that β-catenin activation was indispensable for the nuclear localization and tumour suppression effects of TET2. In addition, the β-catenin pathway activator IM12 and the TET2 activator vitamin C were used simultaneously to enhance the effects of TET2 under low-expression conditions, and synergistic inhibitory effects on the growth of cancer were observed both in vitro and in vivo. Collectively, these data suggest that β-catenin-mediated nuclear localization of TET2 is an important therapeutic target for solid tumours.